Partial
Partial / Needs Review
Patient Risk:
Moderate
Summary
Several dosing/administration and mechanism claims align with the provided label excerpts (dose schedule; PCSK9 mRNA targeting; hepatocyte LDL receptor effects; hypersensitivity contraindication). However, multiple claims about approval dates/EMA authorization, specific clinical trial percentages/populations, class similarity to PCSK9 protein inhibitors, and certain side-effect descriptions are not supported by the provided FDA label excerpts and may be partially speculative relative to what was supplied for auditing.
Category Scores
Accurate Statements
Leqvio is indicated for adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia, as an adjunct to diet.
Supported indirectly only in part: the provided label excerpt states LEQVIO is an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia. The excerpt does not explicitly mention “mixed dyslipidemia” or “adjunct to diet” without exercise.
Leqvio is used to reduce low-density lipoprotein cholesterol (LDL-C).
Supported: label excerpt states LEQVIO reduces low-density lipoprotein cholesterol (LDL-C).
Leqvio is indicated for adults with homozygous familial hypercholesterolemia, as an adjunct to other lipid-lowering treatments.
Partially supported: label excerpt indicates adjunct to diet and exercise to reduce LDL-C; it also includes HoFH (adults and pediatric age 12+). The excerpt provided does not include wording about “as an adjunct to other lipid-lowering treatments.”
Leqvio is a small interfering ribonucleic acid (siRNA) inhibitor of the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9).
Supported in substance: label excerpt states inclisiran directs catalytic breakdown of PCSK9 mRNA; the provided excerpt reflects mechanism affecting PCSK9.
By inhibiting PCSK9, Leqvio increases the number of LDL receptors on the liver, leading to enhanced clearance of LDL cholesterol from the bloodstream.
Supported: label excerpt (12.1) states increased LDL-C receptor recycling/expression on hepatocyte cell surface, increased LDL-C uptake, and lowering LDL-C levels in circulation.
The recommended dosage for Leqvio involves an initial dose, a second dose at 3 months, and then a maintenance dose every 6 months thereafter.
Supported: label excerpt (2.1) specifies 284 mg subcutaneous injection initially, again at 3 months, then every 6 months.
Leqvio is administered subcutaneously every six months after initial doses.
Supported: consistent with every-6-month maintenance dosing after initial and 3-month dose (2.1).
Inclisiran targets PCSK9 mRNA within hepatocytes.
Supported in substance: label excerpt says inclisiran directs catalytic breakdown of mRNA for PCSK9 and increases receptor expression on hepatocyte cell surface.
Targeting PCSK9 mRNA leads to a sustained reduction in PCSK9 protein levels, thereby increasing LDL receptor expression and LDL-C uptake.
Partially supported: label excerpt (12.1) supports increased LDL-C receptor recycling/expression and increased LDL-C uptake and lowering LDL-C. The excerpt provided does not explicitly state “sustained reduction in PCSK9 protein levels.”
Leqvio was developed by The Medicines Company, which was subsequently acquired by Novartis.
Not supported by provided label excerpts. The audited excerpts do not include development/ownership history.
Leqvio is similar in class to PCSK9 inhibitors such as evolocumab (Repatha) and alirocumab (Praluent).
Not supported by provided label excerpts: the mechanism/interaction excerpts do not establish “class similarity” to evolocumab/alirocumab.
Leqvio, evolocumab (Repatha), and alirocumab (Praluent) work by targeting PCSK9 protein to lower LDL cholesterol.
Not supported/only partially supported: label excerpt supports inclisiran works via PCSK9 mRNA breakdown and increases LDL-C receptor recycling. The provided label excerpts do not describe evolocumab/alirocumab targeting PCSK9 protein or compare them.
The most common side effects of Leqvio include injection site reactions such as pain, redness, and itching.
Partially supported: provided label excerpt references injection site reaction frequency (e.g., Table 1 showing injection site reaction). The specific elements “pain, redness, and itching” are not explicitly shown in the provided excerpts.
Unsupported Statements
The European Medicines Agency authorized Leqvio (inclisiran) in August 2020.
Not supported by the provided FDA label excerpts.
The recommended dosage for Leqvio involves an initial dose, a second dose at 3 months, and then a maintenance dose every 6 months thereafter.
Supported; included here only because the claim text is already evaluated as supported in accurateStatements—no action needed. (Kept list empty for this item.)
Clinical trials have demonstrated that Leqvio significantly reduces LDL-C levels.
The provided label excerpts do not include the specific clinical trial efficacy wording or statistical significance statements.
In the ORION-9 study, Leqvio reduced LDL-C by 54% at 18 months compared to placebo in patients with heterozygous familial hypercholesterolemia.
Not supported by the provided label excerpts.
In the ORION-10 study, Leqvio reduced LDL-C by 52% at 18 months in patients with atherosclerotic cardiovascular disease or equivalent risk in the US.
Not supported by the provided label excerpts.
In the ORION-11 trial, conducted in Europe, Leqvio reduced LDL-C by 45% at 18 months in a similar patient population.
Not supported by the provided label excerpts.
Other reported side effects of Leqvio can include cold symptoms, diarrhea, and joint pain.
Not supported by the provided label excerpts (no explicit linkage of these symptoms to reported adverse reactions in the excerpted text).
Leqvio received approval from the U.S. Food and Drug Administration (FDA) in December 2020.
Not supported by the provided FDA label excerpts.
Contradictions
Important Omissions
No mention of contraindication for prior serious hypersensitivity reaction to inclisiran or excipients (and examples such as anaphylaxis/angioedema).
Importance:
Moderate
No mention of administration details beyond dosing interval (e.g., injection site selection limitations; administer by healthcare professional; inspect solution; do not inject into active skin disease/injury).
Importance:
Moderate
No mention of pregnancy warning (discontinue when pregnancy is recognized) or lack of data; no mention of pediatric age threshold (12 years and older).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Most critical dosing and core mechanism statements align with the provided label excerpts. However, the response omits key safety-related label content (hypersensitivity contraindication details; administration instructions; pregnancy/pediatric restrictions). Several adverse reaction statements are not supported by the provided excerpts, reducing label fidelity.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partial / Needs Review
Primary Issue
Multiple claims (EMA/FDA authorization dates, ORION trial endpoints/percentages, specific adverse reaction symptoms, and class comparison to evolocumab/alirocumab) are not supported by the provided FDA label excerpts, and key safety/administration/pediatric/pregnancy label elements are omitted.
Suggested Improvement
Restrict claims to what is explicitly supported by the provided label excerpts (indication wording, dosing schedule, mechanism, hypersensitivity contraindication, and label-supported adverse reaction summaries). Add missing label safety/administration and population eligibility information (pregnancy discontinuation language, pediatric age 12+ thresholds, and hypersensitivity contraindication). Remove or qualify unsupported trial percentage and regulatory-history claims.